S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:CMPI

Checkmate Pharmaceuticals (CMPI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$10.50
▼
$10.50
50-Day Range
$10.37
▼
$10.50
52-Week Range
$2.00
▼
$10.50
Volume
N/A
Average Volume
142,261 shs
Market Capitalization
$231.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

CMPI stock logo

About Checkmate Pharmaceuticals (NASDAQ:CMPI) Stock

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive CMPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CMPI Stock News Headlines

May 26, 2022 | tmcnet.com
University of Iowa Holden Comprehensive Cancer Center Presents
May 26, 2022 | finance.yahoo.com
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 8, 2023 | Behind the Markets (Ad)
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
May 18, 2022 | apnews.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPI
May 13, 2022 | seekingalpha.com
Checkmate Pharmaceuticals GAAP EPS of -$0.73 beats by $0.02
May 13, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 | apnews.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates NLSN, CMPI, SBOW
April 20, 2022 | msn.com
Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M
June 8, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
April 20, 2022 | barrons.com
Shareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Regeneron
April 19, 2022 | bizjournals.com
Checkmate stock quadruples on news of Regenerate acquisition
April 19, 2022 | finance.yahoo.com
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today
April 19, 2022 | stockhouse.com
CMPI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Checkmate Pharmaceuticals, Inc. Is Fair to Shareholders
April 19, 2022 | marketwatch.com
Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal >CMPI
April 8, 2022 | tmcnet.com
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with
April 8, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 8, 2022 | nz.finance.yahoo.com
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 8, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
February 10, 2022 | bizjournals.com
The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars game
February 9, 2022 | seekingalpha.com
Checkmate Pharmaceuticals appoints Alan Bash as President, CEO
February 9, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
January 31, 2022 | nasdaq.com
Checkmate Pharmaceuticals, Inc. Common Stock (CMPI)
January 31, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
January 7, 2022 | nasdaq.com
Here's Why We're A Bit Worried About Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn Situation
January 3, 2022 | finance.yahoo.com
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
December 20, 2021 | finance.yahoo.com
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
November 15, 2021 | finance.yahoo.com
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
See More Headlines


CMPI Company Calendar

Last Earnings
11/12/2021
Today
6/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPI
CUSIP
N/A
CIK
1651431
Web
www.checkmatepharma.com
Phone
617-682-3625
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,400,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-83.92%
Return on Assets
-74.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.20
Quick Ratio
5.20

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.50 per share
Price / Book
4.20

Miscellaneous

Outstanding Shares
22,038,000
Free Float
8,242,000
Market Cap
$231.40 million
Optionable
Not Optionable
Beta
-4.81

Key Executives

  • Mr. Robert F. Dolski (Age 52)
    CFO & Principal Accounting Officer
    Comp: $411.7k
  • Dr. James E. Wooldridge M.D. (Age 56)
    Chief Medical Officer
    Comp: $567.29k
  • Mr. Alan Bash (Age 50)
    Pres, CEO & Director
  • Dr. Arthur M. Krieg M.D. (Age 65)
    Ph.D., Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director
  • Ms. Katherine A. Eade (Age 48)
    Gen. Counsel
  • Dr. Kleem Chaudhary Ph.D. (Age 46)
    Chief Bus. Officer

Key Competitors

View All Competitors













CMPI Stock - Frequently Asked Questions

How were Checkmate Pharmaceuticals' earnings last quarter?

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) issued its quarterly earnings data on Friday, November, 12th. The company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $0.02.

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Oak Street Health (OSH), Adobe (ADBE), Berkshire Hathaway (BRK.A), Lockheed Martin (LMT), Tesla (TSLA), Acutus Medical (AFIB), BigCommerce (BIGC), Freeline Therapeutics (FRLN), Rocket Companies (RKT) and Agnico Eagle Mines (AEM).

When did Checkmate Pharmaceuticals IPO?

(CMPI) raised $75 million in an IPO on Friday, August 7th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and BTIG was co-manager.

What is Checkmate Pharmaceuticals' stock symbol?

Checkmate Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMPI."

What is Checkmate Pharmaceuticals' stock price today?

One share of CMPI stock can currently be purchased for approximately $10.50.

How much money does Checkmate Pharmaceuticals make?

Checkmate Pharmaceuticals (NASDAQ:CMPI) has a market capitalization of $231.40 million. The company earns $-61,400,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

How can I contact Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals' mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.checkmatepharma.com. The company can be reached via phone at 617-682-3625 or via email at rdolski@checkmatepharma.com.

This page (NASDAQ:CMPI) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -